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Abstract 
During the past decade idiopathic venous thromboembolism has become a separate entity, a chronic illness which has 
required prolonged anticoagulation and other prevention strategies to avoid recurrences.  
 This article reviews recent developments regarding unprovoked venous thromboembolism and its relation with thrombophilia.  
 In the beginning, the latest definition of idiopathic venous thromboembolism is presented. The article continues with statistics about 
thrombophilia, related venous thromboembolism, and a classification of major thrombophilic factors according to their intrinsic risk of 
thrombosis and of thrombotic recurrences. Great interest is given to the predictors of recurrence and the importance of prolonged 
anticoagulation is underlined. The antiphospholipid antibody syndrome, the most common acquired thrombophilia, is presented 
separately. The revised diagnosis criteria are discussed. Some characteristics of the antiphospholipid syndrome are worth 
presenting: the risk of both venous and arterial thrombosis, the high risk of thrombotic recurrence and the diversity of 
antiphospholipid antibodies. 
   Patients experiencing idiopathic venous thromboembolic event have a great risk of recurrence, and highly benefit from long 
time anticoagulation. Natural coagulation inhibitors deficiencies, homozygous factor V Leiden and prothrombin G20210A and the 
antiphospholipid syndrome, increase the risk of first venous thrombosis and their recurrences and require adequate prevention. 
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Abbreviations: VTE – venous thromboembolism, HRT – hormone replacement therapy, AVK – antivitamin K, FVL – 
factor V Leiden, PT G20210A – prothrombin G20210A, TAFI – thrombin activatable fibrinolysis inhibitor, PAI-1 - 
plasminogen activator inhibitor 1, T- PA – tissue plasminogen activator, APS – antiphospholipid syndrome, LA – lupus 
anticoagulant, Aβ2GP1 – anti β2 glycoprotein 1. 
Background 
Even if it is a common disease, venous 
thromboembolism may sometimes be challenging. In case 
of a patient with deep venous thrombosis or pulmonary 
embolism many questions arise: which was the cause, 
which is the most appropriate treatment, how long the 
treatment should be or how can we prevent a thrombotic 
recurrence. Since 1856 when  Rudolf Virchow first 
described the three factors involved in the thrombotic 
process – hypercoagulability, hemodynamic changes 
(stasis, turbulence), endothelial injury/dysfunction -  a lot 
of progress has been made in understanding 
thrombosis.[1] Since 1965 when Egeberg described  for 
the first time a case of familial thrombosis determined by 
antithrombin deficiency, numerous mutations causing 
hypercoagulability have been discovered. [1] 
 
Idiopathic Venous Thromboembolism 
Unprovoked (idiopathic) VTE definition differs from 
study to study, the most recent being published in the 
French consensus guideline in 2009 [1], where idiopathic 
VTE is defined as being the VTE which occurs in the 
absence of triggering circumstances classified as it 
follows:  
(a)  Major triggering circumstances: 
Plaster cast immobilization and / or fracture of a 
lower limb or surgery under general anesthesia 
lasting for more than 30 minutes or bed rest for 
more than three days, occurring in three 
previous months or active cancer in the two 
preceding years. 
(b)  Moderate or minor triggering circumstances: 
Pregnancy or post-partum, oestroprogestative 
contraception or HRT in the year preceding the 
VTE, a journey lasting for more than 6 h. [1] 
The incidence of unprovoked VTE varies between 
25% and 50% as reported in different studies. [2] The 
studies demonstrated that in almost 50% of first VTE Journal of Medicine and Life Vol. 4, No. 1, January‐March 2011 
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event, a thrombophilic factor could be identified. [3] 
Testing for thrombophilia is recommended, but there are 
controversies with respect to the way thrombophilia 
influences the anticoagulant treatment duration, the risk of 
recurrence, the benefice of testing the asymptomatic 
relatives.  
 
Thrombophilic factors 
Recently, a stratification of  major thrombophilic 
factors according to their risk of thrombosis has been 
published.[4] Based on this study the most thrombogenic 
factors are  deficiencies of natural coagulation inhibitors 
(antithrombin deficiency, protein C deficiency, protein S 
deficiency).[4]  Also, a high risk of thrombosis has been 
noticed in the case of antiphospholipid  syndrome and in 
the homozygous forms of factor V Leiden and 
prothrombin G20210A. Heterozygous forms of factor V 
Leiden and prothrombin G20210A and high levels of 
factor VIII are responsible only for a moderate increase of 
the risk of thrombosis. [4] Considering these, it becomes 
obvious that acquired risk factors for thrombosis have an 
important role and that, in many cases, venous 
thromboembolism occurs in the presence of both acquired 
and genetic thrombotic factors.   
Testing for thrombophilia is recommended in:  
‐  Unprovoked VTE  before 60 years old or VTE 
occurring in the absence of major triggering 
circumstances; 
‐  Family history of thromboembolic disease; 
‐  Thrombosis in unusual sites: cerebral veins, 
visceral veins thrombosis, upper extremities vein 
thrombosis etc.;  
‐  Obstetric pathology like: recurrent miscarriages, 
stillbirths or dismature  newborns; 
‐  Abnormal laboratory tests without apparent 
causes (prolonged aPTT); 
‐  Skin necrosis after initiation of AVK treatment. [5] 
Another problem is whether testing for 
thrombophilia, the asymptomatic relatives of patients with 
certain thrombophilic defects, is needed. The Belgian 
Society on Thrombosis guidelines recommends a well-
balanced decision, considering the stress, anxiety and 
over protective attitudes generated by thrombophilia.[5] 
French consensus guidelines recommends to test the 
asymptomatic relatives when the index case suffers from 
antithrombin deficiency (except for the mutation of the 
heparin binding site, the IIbHBS variant), protein C and S 
deficiencies and also in the case of homozygous  or 
double heterozygous forms of factor V Leiden and PT 
G20210A. It seems to be useless to test the 
asymptomatic relatives of an index case with 
heterozygous form of FVL or PT G20210A, because the 
studies revealed that the risk of thrombotic events is not 
significantly higher than the risk of other persons with the 
same risk factors from the general population. That 
explains why family studies are not recommended in case 
of moderate thrombophilic factors with high prevalence in 
general population. Also, considering the costs, it is 
recommended to begin the screening of asymptomatic 
relatives with the mutation found in the index case. If the 
test is negative, the recommendation is to stop the 
screening, but if the test is positive, the screening should 
continue, as combined thrombophilia might coexist and 
increase the risk of thrombosis. 
There are also problems regarding the moment 
of testing for thrombophilia in order to obtain a reliable 
result, especially in patients with a first VTE. 
During the acute thrombotic episode, many 
factors may distort the results: factor’s VIII levels may be 
higher than normal (acute phase reactant), protein C, S 
and antithrombin levels may be lower than normal. Also 
antithrombin levels may be under the inferior limit during 
the therapy with unfractionated heparin. Protein C and S 
levels (which are vitamin K dependent proteins) are 
reduced by vitamin K antagonists, explaining why testing 
for their deficiencies is not recommended while using 
anticoagulants.[6] According to the general 
recommendations, the most appropriate moment for 
thrombophilia screening is at the end of the anticoagulant 
treatment, usually 4 or 6 weeks later.[5,6] However, some 
tests could be performed in the acute episode: lupus 
anticoagulant and anticardiolipin antibodies (IgM and 
IgG), protein C, S and APCR in case of skin necrosis, 
antithrombin in case of thrombosis at unusual sites or at 
young age. [5] Genetic analysis for factor V Leiden and 
PT G20210 detection may be performed during the acute 
episode but considering their costs, it is preferable to wait 
and screen initially for APCR and for natural 
anticoagulants deficiencies. 
Another problem regarding thrombophilia is if 
screening should be performed before starting oral 
contraception and hormone replacement therapy. With 
respect to this problem, the French consensus guideline 
sustains that the presence or absence of thrombophilia 
does not change the clinical attitude in the context of the 
prescription of an oral contraceptive to a patient with 
history of VTE, as taking oral oestroprogestative 
contraceptives or hormone replacement is contraindicated 
in women with previous VTE. However, there are no 
indications if screening for thrombophilia should be done 
before taking contraceptives in women without a history of 
VTE. 
 
Predictors of recurrence  
There are also controversies regarding the 
length of the anticoagulant treatment in patients with 
venous thromboembolism and thrombophilia. As the risk 
of thrombosis is higher than normal, it seems reasonable 
to administrate anticoagulants for a longer period of time 
in order to prevent recurrences. Many researchers 
focused on this problem, but, unfortunately, the results 
are not as they expected, because some studies failed 
due to the slow inclusion rate, other used different cut off 
values and their result could not be compared or had Journal of Medicine and Life Vol. 4, No. 1, January‐March 2011 
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divergent conclusions, others were too small to have a 
powerful statistical significance or used different 
definitions for “unprovoked VTE” or for “family history of 
VTE”. After analyzing the existing studies, the French 
group of specialists concluded that in the assessment of 
the risk of thrombosis recurrence the most important step 
is to determine whether the episode was provoked or not, 
the unprovoked (idiopathic) character of VTE being a 
strong indicator of recurrence, irrespective of any 
knowledge of possible thrombophilia. In a prospective 
cohort study of 570 patients with a first episode of VTE, 
Baglin et al demonstrated that at two years after ceasing 
the anticoagulant therapy, the cumulative recurrence rate 
was 11%. [7]. The statistical analyses revealed that the 
most important predictor of recurrence was the presence 
of clinical risk factors for thrombosis. The recurrence after 
a surgical related VTE was of 0%, and the highest 
recurrence rate was noticed in the unprovoked episodes 
of VTE (19.4%, p<0.001). Also, the results showed that in 
patients with unprovoked VTE or with a non-surgical 
related VTE, the recurrence rate did not differ between 
patients with or without thrombophilia.[7] 
Another predictor of recurrence after a first VTE 
event is the age. It is very well-known that the incidence 
of VTE increases with age, and about 70% of patients 
presenting a first episode of VTE are over 60 years 
old.[1]. The rate of recurrence is higher when the first 
episode of VTE occurs before 60 years old, as studies 
proved. [1]. Also, the French guide underlines that in the 
age group over 70 years, the presence of thrombophilia 
does not seem to influence the risk of recurrence due to 
age, particularly with regard to factor V Leiden and 
FIIG20210A polymorphisms. [1]. Regarding the natural 
coagulation inhibitors deficiencies, conclusions are 
difficult to be drawn because of the lack of information, 
most of it coming from family studies and not from the 
general population. From the available data, it results that 
antithrombin deficiency, protein C deficiency and protein 
S deficiency have a recurrence risk of 40% at 5 years and 
of 55% at 10 years comparative to 11% at 5 years and 
25% at 10 years for factor V Leiden, Prothrombin 
G20210A and high factor VIII. [4] In Brower et al study 
concerning 130 patients with natural anticoagulants 
deficiencies, with first VTE, the annual ratios of 
recurrence were of 8.4% for protein S deficiency, 6% for 
protein C deficiency and 10% for antithrombin deficiency, 
compared to an estimated recurrence rate of 1% in 
patients without a deficiency. [8]They concluded that 
patients with coagulation inhibitors deficiencies have a 
high absolute risk of recurrence and that this risk is 
increased after a first spontaneous event and when 
associated with other thrombophilic defects.[8] 
Another problem is that inhibitors deficiencies 
are caused by different mutations, each of them 
determining a different risk of thrombosis, which explains 
the variety of phenotypes among people with the same 
anticoagulant deficiency. An edifying example is 
antithrombin deficiency, recognized as one of the most 
important risk factors for thrombophlia-induced 
thrombosis. Until now, more than 150 mutations of the 
antithrombin gene have been identified. Most of them are 
found in the heterozygous form. The homozygous cases 
are very rare (less than 20 reported) and are associated 
with severe and early onset of the thromboembolic 
disease (with both venous and arterial thrombosis) and 
often without a family history of thrombosis. The risk of 
thrombosis induced by the type II deficiency of heparin 
binding site (IIbHBS variant) is very low, compared to 
other congenital deficiencies of antithrombin. It has also 
been noticed that only the mutations that in the 
heterozygous form induce a low or moderate thrombotic 
risk could be seen in a homozygous form, otherwise the 
homozygous status is lethal. 
Trying to answer the question: “When is the best 
moment to stop oral anticoagulation treatment?”, Palereti 
et al suggested that  D-Dimer assay may be used in the 
appreciation of the duration of oral anticoagulant 
treatment and to optimize prevention of recurrent venous 
thromboembolism. They evaluated 599 patients with a 
previous VTE, who were repeatedly tested for D-Dimer 
levels after interrupting oral anticoagulation and were also 
screened for most frequent thrombophilic alterations. 
They concluded that normal D-Dimer levels measured 
one month after oral anticoagulant treatment withdrawal 
have a high negative predictive value (92.9%) for 
recurrence in patients with idiopathic VTE and in carriers 
of inherited thrombophilia. Increased D-Dimer levels were 
associated with a significantly higher hazard ratio for VTE 
recurrence. [9] 
Another method, which seems to help the 
clinician establish the risk of recurrence, is examination of 
residual venous thrombosis on ultrasound. Patients with 
residual thrombosis have a higher risk of recurrence that 
those without remaining thrombi.  
However, until now, neither the D-Dimer levels 
nor the residual thrombosis are precise methods to 
predict which patients will experience a recurrence after 
the cessation of the anticoagulant treatment. 
 
Anticoagulant treatment in idiopathic VTE 
S. Goldhaber underlines the importance of 
considering the idiopathic VTE as a chronic disease and 
insists on the benefits of indefinite duration of 
anticoagulant treatment, possibly for a lifetime. His 
affirmations are based on studies like PREVENT, ELATE 
and THRIVE. [10] The PREVENT (Prevention of 
Recurrent Venous Thromboembolism) trial demonstrated 
the advantages of low-intensity anticoagulation with 
warfarin (target INR of 1.5-2.0)  in 508 patients with 
idiopathic VTE after six months of standard 
anticoagulation. The trial was interrupted after two years 
due to the obvious benefits noticed in the warfarin group 
compared to the placebo group. The ELATE (Extended 
Low-Intensity Anticoagulation for Thromboembolism) Journal of Medicine and Life Vol. 4, No. 1, January‐March 2011 
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study of 738 patients with unprovoked VTE compared the 
benefits of low-intensity warfarin anticoagulation (target 
INR between 1.5 and 1.9) to standard anticoagulation 
(target INR of 2.0 – 3.0). The patients were included after 
they had completed at least three months of conventional 
anticoagulation and were followed up for a medium of 2.4 
years. The results showed a likelihood of recurrence of 
2.8 higher in the low-intensity anticoagulation group than 
in the standard anticoagulation one. Another important 
finding was that the adverse effects of anticoagulation 
(hemorrhage) occurred with a similar frequency in the two 
groups. The THRIVE study demonstrated the benefits of 
using a thrombin direct inhibitor (ximelagatran) in 
decreasing the recurrent thrombotic events in 1233 
patients with idiopathic VTE after six months of standard 
warfarin anticoagulation. Regarding the drug used in 
THRIVE trial – ximelagatran – it has to be mentioned that 
in 2006 its manufacturer retired the product from the 
market because of reports of hepatotoxicity during trials. 
However, other molecules from the same class such as 
dabigatran seem to have the same beneficial effects and 
less aggressive side effects. 
Considering the predisposition for thrombosis in 
thrombophilic patients, one can argue that thrombophilia 
may also induce an increased risk of VTE recurrence 
while on warfarin treatment and that a high intensity of 
anticoagulation may be needed in order to prevent the 
recurrent events. A substudy of the ELATE trial 
demonstrated that single or multiple thrombophilic defects 
are not associated with a higher risk of VTE recurrence 
during anticoagulant treatment, with the possible 
exception of the antiphospholipid antibodies. [11]  
Rare thrombophilic factors 
Regarding the rare thrombophilic defects like 
dysfibrinogenemia, elevated TAFI, elevated PAI-1, t-PA 
deficiency, few data are available, mostly as case reports. 
They are not part of the screening analyses and due to 
their low prevalence, large studies are impossible to be 
realized, making a discussion about their influence on the 
recurrence risk rather difficult.  
High factor IX, high factor XI, high TAFI are not 
independent risk factors for venous thromboembolism, but 
become risk factors when associated with high factor VIII 
levels. [4] 
It has been demonstrated that elevated factor 
VIII, generally defined as above 90 percent, determines 
an increased risk of recurrent VTE.[1] In different studies, 
this risk is clearly related to the plasma concentration of 
factor VIII and the threshold used to define how a high 
factor VIII influences the risk of recurrence, and explains 
the variable results between different studies. 
Hyperhomocysteinemia is also a well-known risk 
factor for both venous and arterial thrombosis. Severe 
hyperhomocysteinaemia has been noticed in 
homocystinuria, a pathology caused by enzymatic 
deficiencies, which affect the homocystein metabolism. 
Such patients often experience an arterial or venous 
thrombosis before the age of 30 years. As for factor VIII, 
there are also problems with the definition of 
hyperhomocysteinaemia. Generally, it is considered when 
plasma concentration is higher than 95 percent. The 
Austrian Study on Recurrent Venous Thromboembolism 
found that hyperhomocysteinemia represents a risk factor 
for recurrent VTE [1], while others, like Leiden 
Trombophilia Study, disagree. [1] 
The Antiphospholipid Syndrome 
A special attention must be given to the 
antiphospholipid syndrome. It represents an acquired 
thrombophilic disorder that can be seen as a distinct entity 
(primary antiphospholipid syndrome) or in association with 
systemic lupus erythematosus or other autoimmune 
diseases (secondary antiphospholipid syndrome). It 
increases both the risk of venous and arterial thrombosis. 
The diagnosis was established based on the Sapporo 
criteria. According to these, definite antiphospholipid 
syndrome is considered when at least one clinical 
criterion and one laboratory criterion are met.  The clinical 
criteria refer to the presence of (a) vascular thrombosis 
(venous, arterial or small vessels thrombosis confirmed by 
imagistic  procedures or hystopathologic exam) or to (b) 
pregnancy morbidity (premature neonates due to severe 
pre-eclampsia or severe placental insufficiency; fetal 
death at or beyond 10 weeks of gestation; three or more 
spontaneous abortions before the 10th week of gestation). 
The laboratory criteria refer to the presence of 
anticardiolipin antibodies (Ig G or Ig M) at least in two 
determinations, at least six weeks apart and in the 
presence of lupus anticoagulant, and also, on two or more 
occasions with a minimum of six weeks distance between 
them.  
Recently, at a workshop in Sydney, Australia, the 
laboratory criteria have been modified by also including 
the antibodies against β2 – glycoprotein I in the laboratory 
classification criteria in addition to lupus anticoagulant and 
anticardiolipin antibodies. In addition, the role of 
antiprothrombin antibodies and 
antiphosphatidylethanolamine antibodies was considered 
poorly investigated in order to include these antibodies in 
the diagnostic criteria. More recently, a group of Italian 
researchers, developed o study based on WAPS (warfarin 
in antiphospholipid syndrome study) in order to explore 
the relationship between single/multiple positive tests for 
LA and IgG/IgM for aCL, aβ2GPI, antiprothrombin 
antibodies, antiprotein S and antiannexin AV antibodies 
and thrombosis and obstetric complications.[12] They 
concluded that the introduction of aβ2GPI antibodies in 
the antiphospholipid syndrome diagnosis criteria was well 
justified and, went further, and proposed the replacement 
of aCL antibodies with aβ2GPI antibodies in the 
laboratory criteria, underlining the importance of IgG 
isotype of aβ2GPI antibodies. They also suggested that Journal of Medicine and Life Vol. 4, No. 1, January‐March 2011 
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antiprothrombin and antiannexin AV antibodies could be 
considered as future candidates for the antiphospholipid 
syndrome criteria. [12] 
After a first thrombotic episode (venous or 
arterial), the risk of recurrence is significant in patients 
with persistent antiphospholipid antibodies. Khamashata 
et al reported that 69% of the patients with APS included 
in their study suffered a total of 186 recurrences, with the 
median time between the initial thrombosis and the first 
recurrence of 12 months.  The highest rate of recurrence 
was noticed during the first six months after warfarin 
discontinuation. They concluded that the risk of 
thrombosis recurrence in patients with APS is high and 
long-term treatment is justified. They also recommended 
high-intensity anticoagulation for these patients. [13] 
Later, Finazzi et al demonstrated in WAPS study that 
high-intensity warfarin treatment was not superior to 
conventional anticoagulant treatment and it significantly 
increased the bleeding complications. [14] 
Another problem is which is the best treatment in 
cases of arterial thrombosis (for example 
noncardioembolic stroke or transient ischemic attack) in 
patients with APS: antiplatelet agent or oral 
anticoagulant? Few randomized control trials are focusing 
on this problem, so, it should be treated according to the 
guidelines for stroke or myocardial infarction 
management. Moreover, secondary thromboprophylaxis 
measures such as hypertension control and lowering LDL 
– cholesterol levels are of great importance. [15] 
Noncerebral artery thrombosis such as renal thrombosis 
is recommended to be treated with moderate intensity oral 
anticoagulation indefinitely. [15] 
Conclusions 
Idiopathic VTE requires a special attention from 
the clinician as he deals with a chronic patient who needs 
to be carefully investigated, periodically monitored, and 
treated for a long time, sometimes for a lifetime. A positive 
diagnosis of thrombophilia influences the therapy if 
endogenous anticoagulants deficiencies, homozygous 
forms of factor V Leiden and prothrombin G20210A or 
antiphospholipid syndrome are found.  Treatment should 
be individualized not only according to the type of 
thrombophilia but also to the patient’s comorbidities and 
additional risk factors. 
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